Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria:~* 18 years of age or older at time of consent~* Active Psoriatic Arthritis~* Clinically stable, plaque psoriasis involving more than 10% of the body surface area~Exclusion Criteria:~Exclusion Criteria:~* Evidence of skin conditions other than psoriasis that would interfere with skin examinations.~* Systemic anti-psoriasis therapy or DMARD within 28 days of study drug initiation~* Prior exposure to any TNF-inhibitor, including etanercept

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Period 1 (Double Blind): 50mg bi-weekly (BIW) for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW).
- B (Type: ACTIVE_COMPARATOR): Period 1 (Double Blind): 50mg weekly (QW) with matching placebo for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW) for weeks 13-24.

Based on this trial design, predict the completion outcome and termination type (if applicable).